{'fraction_non_alphanumeric': 0.012269938650306749, 'fraction_numerical': 0.003067484662576687, 'mean_word_length': 5.465346534653466, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Intravesical therapy with adriamycin in urothelial dysplasia and early carcinoma in situ.

The authors studied the effect of instilling Adriamycin intravesically in 21 patients with urothelial dysplasia and early carcinoma in situ. The effectiveness of the treatment was assessed by repeated urine cytology, cystoscopy and repeated biopsy of the bladder mucosa. No serious side effects were noted. Adriamycin causes the death of malignant cells, general improvement in the appearance of the bladder mucosa at cystoscopy and histologic evidence of endothelial damage to the bladder mucosa. The cytologic changes continue for many months after treatment.